Glycomic immunotherapies

Nature appears to have taken full advantage of the vast diversity of glycans expressed in organisms by evolving protein modules to recognize discrete glycans that mediate specific physiological or pathological processes. Excluding glycan-specific antibodies, GBPs broadly into two major groups such as lectins and glycosaminoglycan-binding proteins. Most lectins are members of families with defined “carbohydrate-recognition domains” (CRDs) that apparently evolved from shared ancestral genes, often retaining specific features of primary amino acid sequence or three-dimensional structure. Thus, new family members can be identified by searching protein sequence or structural databases.

    Related Conference of Glycomic immunotherapies

    Glycomic immunotherapies Conference Speakers